BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35384641)

  • 1. Palovarotene: First Approval.
    Hoy SM
    Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
    Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
    BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
    Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
    J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
    Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
    J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
    Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
    Elife; 2018 Sep; 7():. PubMed ID: 30226468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
    Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
    Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.
    Pacifici M
    Bone; 2018 Apr; 109():267-275. PubMed ID: 28826842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
    Goldhamer DJ; Lees-Shepard JB
    Elife; 2019 Jan; 8():. PubMed ID: 30698142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
    Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
    Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.
    Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA
    Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification.
    Huang J; Wu J; Lin J; Li C; Tang B; Xiao H
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):881-892. PubMed ID: 35638441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
    Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
    BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoid Agonists in the Targeting of Heterotopic Ossification.
    Pignolo RJ; Pacifici M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.
    Wheatley BM; Cilwa KE; Dey D; Qureshi AT; Seavey JG; Tomasino AM; Sanders EM; Bova W; Boehm CA; Iwamoto M; Potter BK; Forsberg JA; Muschler GF; Davis TA
    J Orthop Res; 2018 Apr; 36(4):1135-1144. PubMed ID: 28960501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.